Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stake Boosted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 128.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,421 shares of the biopharmaceutical company’s stock after purchasing an additional 8,683 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Celldex Therapeutics were worth $390,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB lifted its position in shares of Celldex Therapeutics by 52.9% in the 4th quarter. Handelsbanken Fonder AB now owns 21,100 shares of the biopharmaceutical company’s stock worth $533,000 after buying an additional 7,300 shares during the last quarter. Values First Advisors Inc. raised its stake in Celldex Therapeutics by 20.0% during the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock worth $733,000 after acquiring an additional 4,837 shares during the period. Sovran Advisors LLC bought a new position in Celldex Therapeutics in the fourth quarter worth about $2,867,000. KBC Group NV boosted its stake in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,647 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 4,967 shares during the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on CLDX. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price target on the stock. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $19.35 on Tuesday. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -7.53 and a beta of 1.60. The stock’s fifty day moving average is $23.75 and its 200-day moving average is $28.80. Celldex Therapeutics, Inc. has a one year low of $19.31 and a one year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.